Dongwha Pharm.Co.,Ltd (KRX:000020)

Market Cap	173.51B
Revenue (ttm)	428.48B
Net Income (ttm)	7.67B
Shares Out	27.72M
EPS (ttm)	276.85
PE Ratio	22.61
Forward PE	n/a
Dividend	180.00 (2.88%)
Ex-Dividend Date	Dec 27, 2024

Volume	27,891
Average Volume	51,251
Open	6,250.00
Previous Close	6,240.00
Day's Range	6,200.00 - 6,270.00
52-Week Range	5,950.00 - 9,980.00
Beta	1.11
RSI	53.20
Earnings Date	Feb 21, 2025

About Dongwha Pharm.Co.,Ltd

Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and tooth, hepatic protectors, nutrients, tonics, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1897
• Employees: 816
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000020

Financial Performance

In 2023, Dongwha Pharm.Co.,Ltd's revenue was 361.11 billion, an increase of 6.08% compared to the previous year's 340.43 billion. Earnings were 27.44 billion, an increase of 34.61%.